Helen of Troy Q2
This article was originally published in The Rose Sheet
Executive Summary
Personal care sales rose 10% to $111 mil. during the second quarter (ended Aug. 31), and grew 7.4% to $216.3 mil. for the first half of the year, firm reports Oct. 5. Net sales in Q2 were up 12.9% to $147.2 mil., while net earnings advanced 15% to $10.9 mil. Results were positively impacted by the initial sell-through of new products at retail, Helen of Troy says. Net revenues in the first half of the year increased 7.7% to $277.6 mil., while net earnings fell 12.2% to $17.6 mil. Helen of Troy reaffirmed its previous guidance projecting full-year (ending Feb. 28) revenues will be in the range of $600 mil.-$620 mil. (1"The Rose Sheet" May 15, 2006, p. 8)...
You may also be interested in...
Finance In Brief
Church & Dwight Q1: Divesture of deodorant and toothpaste businesses is "not on our radar," CEO James Craigie says in response to analyst question during first quarter sales and earnings call May 9. U.S. consumer sales increased 5.5% to $314 mil., with gains in other segments "partially offset by lower toothpaste and antiperspirant sales," company says in earnings release. In Q2, Mentadent and Arm & Hammer toothpaste launches will be backed by new ad campaigns, while Nair lotions will have increased marketing support, Craigie says. Personal care products were down .2% to $130.2 mil. First quarter sales of $442.4 mil., representing a 5.2% increase, include $12.3 mil. from acquisition of a skin care operation in Brazil and Procter & Gamble's SpinBrush battery-operated toothbrush business (1"The Rose Sheet" Sept. 19, 2005, p. 6). Net income increased 7% to $39.9 mil. including $2.1 mil. pretax stock option charge, and operating profit was up 7.6% to $72.3 mil. including the stock option charge...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.